Literature DB >> 8251029

Treatment of the post-mastectomy pain syndrome with topical capsaicin.

Dario Dini1, Gianfilippo Bertelli, Alberto Gozza, Gilberto G Forno.   

Abstract

Twenty-one patients with post-mastectomy pain syndrome (PMPS) were entered in an open-label trial of topical 0.025% capsaicin treatment (3 daily applications for 2 months). Out of 19 evaluable patients, 2 (10.5%) reported complete disappearance of all symptoms, and 11 (57.9%) had a reduction of pain which was never worse than mild at the end of treatment. Three months after cessation of treatment, 11 of 13 of the responding patients continued to have good pain relief, with only 1 continuing to use capsaicin. Treatment was well tolerated with no drop-out due to side effects. This is the first independent confirmation of the usefulness of capsaicin in the PMPS, following the recent publication of a randomized, placebo-controlled clinical study showing significant pain relief with 0.075% capsaicin but not with vehicle cream. Further experimental and clinical research on the properties of capsaicin in other painful peripheral neuropathies is desirable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251029     DOI: 10.1016/0304-3959(93)90213-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  3 in total

Review 1.  Post-breast surgery pain syndrome: establishing a consensus for the definition of post-mastectomy pain syndrome to provide a standardized clinical and research approach - a review of the literature and discussion.

Authors:  Daniel Waltho; Gloria Rockwell
Journal:  Can J Surg       Date:  2016-09       Impact factor: 2.089

2.  The effectiveness of topically applied capsaicin. A meta-analysis.

Authors:  W Y Zhang; A Li Wan Po
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Phantom breast syndrome.

Authors:  Nootan K Shukla; Sushma Bhatnagar
Journal:  Indian J Palliat Care       Date:  2009-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.